Quantcast
Last updated on April 20, 2014 at 0:02 EDT

Latest SIMPLE ANTIBODY Stories

2013-09-19 04:21:07

BREDA, the Netherlands and GHENT, Belgium, September 19, 2013 /PRNewswire/ -- arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody(TM) research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the...

2013-09-17 04:22:16

BREDA, the Netherlands, and GHENT, Belgium, September 17, 2013 /PRNewswire/ -- SIMPLE Antibody(TM) with unique mode of action addressing c-Met positive tumors arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody(TM) product to enter the clinic this year. ARGX-111 is a...

2013-03-25 08:25:56

BREDA, The Netherlands and GHENT, Belgium, March 25, 2013 /PRNewswire/ -- ARGX-112 targets IL22R1, a novel target involved in chronic skin inflammation arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announces that it has progressed ARGX-112, its fourth therapeutic candidate, into formal preclinical development. ARGX-112 is a novel, fully human antibody...

2013-01-07 04:20:31

BREDA, the Netherlands, and GHENT, Belgium, January 7, 2013 /PRNewswire/ -- arGEN-X, a biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, its first SIMPLE Antibody(TM) program to enter the clinic in just three years from initiation of discovery. ARGX-110 is a first-in-class CD70-targeting monoclonal...

2012-10-04 02:26:24

LA JOLLA, Calif., BREDA, Netherlands and GHENT, Belgium, Oct. 4, 2012 /PRNewswire/ -- RuiYi (formerly Anaphore) and arGEN-X BV announced today that arGEN-X has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. Under the agreement, RuiYi will make an upfront payment to arGEN-X consisting of cash and equity. arGEN-X is also eligible to receive additional payments based on the...